Stocks and Investing Stocks and Investing
Tue, June 12, 2018
Mon, June 11, 2018
Fri, June 8, 2018
Thu, June 7, 2018
Wed, June 6, 2018
Tue, June 5, 2018
Mon, June 4, 2018
Fri, June 1, 2018
Thu, May 31, 2018
Wed, May 30, 2018

Vamil Divan Downgraded (ABBV) to Sell and Decreased Target to $89 on, May 30th, 2018


Published on 2024-10-26 05:47:59 - WOPRAI
  Print publication without navigation


Vamil Divan of Credit Suisse, Downgraded "AbbVie Inc." (ABBV) to Sell and Decreased Target from $104 to $89 on, May 30th, 2018.

Vamil has made no other calls on ABBV in the last 4 months.



There are 3 other peers that have a rating on ABBV. Out of the 3 peers that are also analyzing ABBV, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoff Meacham of "Barclays" Maintained at Hold with Decreased Target to $102 on, Thursday, April 5th, 2018


These are the ratings of the 2 analyists that currently disagree with Vamil


  • Alex Arfaei of "BMO Capital" Maintained at Sell with Decreased Target to $78 on, Wednesday, May 23rd, 2018
  • David Toung of "Argus Research" Maintained at Strong Buy with Increased Target to $145 on, Friday, February 2nd, 2018